CHENYSEHealthcare

Public company intelligence preview

CHEMED CORP

62 insider trades surfaced from the last year. This page shows only aggregate signals, not the underlying transactions, people, filings, filters, or AI workspace.

Snapshot

A narrow read on a much deeper workspace.

The preview gives search visitors enough signal to understand coverage. It does not expose transaction records, person-level profiles, filters, comparisons, or analyst workflows.

Insider trades, last 12 months
62
9 filed in the last 30 days
Acquisition / disposition count
32/30
Buy / Sell
Unique insiders active in the last year
14
Current insider positions tracked
29
28 active, 1 exited

Insider compensation

Public aggregate: $5.3M average total compensation across covered insiders.

Governance movement

Public aggregate: 1 governance events in the last year.

Institutional ownership

Public aggregate: 510 holders from the latest quarter.

Restricted sales and governance

Public counts, not the investigation layer.

The full product opens the underlying filings, insider context, historical holdings, comparison tools, and AI analysis.

Restricted-sale filings, 1Y
14
Restricted-sale insiders, 1Y
4
Planned sale shares, 1Y
24.2K
Planned sale value, 1Y
$10.2M
Insiders covered
8
Latest year: 2025
Personnel changes, 1Y
1
Board appointments, 1Y
0
Board departures, 1Y
1

Market context

Basic quote context for the preview.

Price
$426.41
Market cap
$5.7B
Volume
256,953
EPS
$4.84
Revenue
$657.5M
Employees
15.8K

Company note

Context before the data.

Company Overview

Chemed Corp. is a diversified holding company in the Healthcare sector and Medical Care Facilities industry, with two main operating segments: VITAS, a major hospice and palliative care provider, and Roto-Rooter, a large plumbing, drain cleaning, and water restoration services business. The company’s operations are decentralized, while corporate management focuses on capital allocation, financial reporting, legal/tax matters, and leadership selection. Recent 10-Q data shows modest consolidated revenue growth driven by VITAS, while Roto-Rooter experienced softer demand in both residential and commercial activity. Chemed’s business mix creates a balance between a highly regulated, reimbursement-driven healthcare operation and a more cyclical, consumer-facing home services franchise.

Executive Compensation Practices

For Chemed, executive compensation is likely tied closely to a mix of earnings growth, adjusted EBITDA, cash flow generation, and capital allocation execution, since those metrics reflect the performance of both VITAS and Roto-Rooter. At VITAS, compensation incentives may be influenced by days of care growth, Medicare reimbursement rates, gross margin, and control of variable patient-care costs, because small changes in reimbursement or acuity mix can materially affect profitability. At Roto-Rooter, executives may be measured on revenue growth, pricing/mix improvement, advertising efficiency, and margin performance, especially given the competitive and fragmented nature of the home services market. The company’s continued share repurchases, acquisition activity, dividend policy, and debt management also suggest that long-term incentive plans may reward disciplined capital deployment rather than pure revenue expansion.

Insider Trading Considerations

Insider trading patterns at Chemed may be influenced by the company’s exposure to Medicare reimbursement timing, regulatory developments, and seasonal demand trends. Because VITAS revenue depends heavily on government reimbursement and billing cycles, insiders may be particularly attentive to quarterly care-day trends, cap pressures, and payment timing, which can create information advantages around results. Roto-Rooter’s performance can be affected by weather, advertising spend, and consumer demand, so insiders may trade around periods when seasonal or promotional trends become clearer. Given the healthcare regulatory environment, insiders may also face tighter practical trading windows around earnings, reimbursement updates, legal developments, and compliance issues tied to Medicare/Medicaid billing and other healthcare rules.

Unlock the full CHE insider intelligence workspace.

Move from public aggregate counts into transaction-level detail, people, filings, compensation history, ownership shifts, export tools, and AI-assisted analysis.

Individual insider trade details with transaction history
Insider compensation breakdown by position
Institutional holder analysis with quarterly comparisons
Insider holdings with temporal change tracking
Restricted sale filings with details
Governance data and personnel changes
10b5-1 trading plan analysis
AI-powered insights and conversational analysis
Board of directors profiles and governance data
Advanced filtering, sorting, and CSV export
7-day free trial included
Cancel anytime
Public preview vs full product
Trade-level transactions, filing links, codes, and footnotes
Available inside the authenticated dashboard, not on the public SEO preview.
Insider pay tables with role-level and year-over-year context
Available inside the authenticated dashboard, not on the public SEO preview.
Institutional holder shifts, concentration, and quarter comparisons
Available inside the authenticated dashboard, not on the public SEO preview.
Restricted-sale, governance, AI analysis, and export workflows
Available inside the authenticated dashboard, not on the public SEO preview.